TAmiRNA offers hepatomiR® RUO RT-qPCR test kit for novel liver function biomarkers

Diagnostic innovator TAmiRNA has developed the microRNA-based hepatomiR® research-use only (RUO) test kit to meet the urgent need for standardized analysis of three novel microRNA liver biomarkers.

The new kit now provides a highly sensitive and specific RT-qPCR test and software application to obtain high quality results for the analysis of these blood-based biomarkers to assess liver function.

hepatomiR® kit features

TAmiRNA’s hepatomiR® kit is designed for high throughput allowing analysis of up to 12 samples per 96-well or 48 samples per 384-well plate.

The hepatomiR® microRNA panel enables quantitative analysis of three liver-enriched microRNAs hsa-miR-122-5p, hsa-miR- 192-5p, and hsa-miR-151a-5p in plasma samples.

The test is effective on sample volumes as low as 200 µL of platelet-poor plasma, with even lower volumes usable for research (RUO) purposes. Samples can be deep-frozen (-70°C or lower) or fresh (centrifuge plasma within 2 hours of blood collection).

The kit is designed for ease of use and efficiency, using primer-coated 96- or 384-well plates to minimize hands-on time and technical variability.

Fast and simple data analysis is provided by the associated hepatomiR® software application, which can speed analysis time from raw data to final results in under five minutes and converts raw miRNA levels into normalized values and even computes a combined liver function score. This score is currently under clinical investigation for the prediction of postoperative liver dysfunction in liver cancer patients.

hepatomiR® kit advantages

Apart from providing a highly sensitive and specific blood-based biomarker to assess liver function, the new hepatomiR® kit offers several other valuable advantages, and has thus great application potential.

  • as a potential surrogate marker for hepatic vein pressure gradient, and
  • for the prognosis, diagnosis, staging, monitoring and treatment response of chronic or acute liver and metabolic diseases, like
    • Drug-induced liver injury
    • AFLD, NAFLD and NASH
    • Other chronic liver diseases
    • Cardiometabolic syndrome and type-2 diabetes

The hepatomiR® assay enables quantification of 3 liver-informative microRNAs, including the established liver function biomarker miR-122, which is:

  • at least as informative as alanine aminotransferase (ALT) in acetaminophen (APAP)-induced liver injury.
  • useful to discriminate between hepatic and non-hepatic serum ALT elevations, such as muscular toxicity, with pre-clinical data suggesting serum levels of miR-122 increase earlier than ALT levels;
  • significantly increased in acute liver injury (ALI) patients but not chronic kidney disease (CKD) patients.


Click on TAmiRNA hepatomiR® as innovative blood-based liver biomarker  for further information.

Die inhaltliche Verantwortung für diesen Beitrag liegt ausschließlich beim Aussender. Beiträge können Vorhersagen enthalten, die auf Erwartungen an zukünftige Ereignisse beruhen, die zur Zeit der Erstellung des Beitrags in Aussicht standen. Bitte verlassen Sie sich nicht auf diese zukunftsgerichteten Aussagen.

Als Life Sciences Organisation mit Sitz in Wien möchten Sie, dass LISAvienna auf Ihre News und Events hinweist? Senden Sie uns einfach Ihre Beiträge an news(at)lisavienna.at.